The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
175
One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, United States
Percentage of patients who develop macular edema within 90 days following cataract surgery
Time frame: Time to event
Mean change in best-corrected visual acuity (BCVA) from baseline to Day 90
Time frame: Baseline, Day 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.